GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
Renal Cell Carcinoma by Associate Professor Brian Costello, Mayo Clinic, USA
GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.
Renal Cell Carcinoma by Associate Professor Brian Costello, Mayo Clinic, USA
Brian A. Costello, M.D., M.S. is a Consultant in the Division of Medical Oncology at Mayo Clinic Rochester and is an Associate Professor of Oncology and Urology. He received his medical degree from the Medical College of Wisconsin and completed his internal medicine residency at the University of New Mexico School of Medicine. He then completed his medical oncology fellowship at Mayo Clinic. Dr Costello was subsequently a Mayo Clinic Scholar during which time he focused on early phase clinical trials and genitourinary malignancies. Dr Costello is currently the Chair of the Genitourinary Tumor Group of the Division of Medical Oncology at Mayo Clinic. He serves as a member of the NCCN Kidney Cancer Panel, the National Cancer Institute’s Renal Task Force, as well as the GU Cancers Core Committee of the Alliance for Clinical Trials in Oncology. He also previously served on the NCI Prostate Task Force from 2013 to 2016. He is actively involved in clinical and translational research and has a busy practice caring for patients with genitourinary cancers. Dr Costello is actively involved in early drug development, especially in genitourinary malignancies. He is the Lead Investigator of the NCI-sponsored Mayo Phase II Program and is a member of the NCI’s Investigational Drug Steering Committee.
Optimising precision medicine for improved patient outcomes
A closer look at the evolving treatment landscape
Experts' insights on treatment strategies in ER+ metastatic breast cancer settings
Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)
Best practices and interpretation of results in lung and ovarian cancer
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer